A prospective study of wound complications in cancer breast surgery following neoadjuvant chemotherapy

Ashok Kumar, Neeraj Nathani, Shishir Kumar


Background: Neoadjuvant chemotherapy is most of the time suitable for subset of the patients of breast cancer in Indian population. Neoadjuvant chemotherapy may be used to down stage a tumor that is inoperable in its current state, so that curative resection becomes feasible. But also, it can decrease size of operable primary tumour so that breast conserving surgery become possible which has better functional outcome and improves the quality of life. Therefore, there is a need to improve understanding of potential for post-operative complications in recipients of Neoadjuvant chemotherapy. Given that neutropenia is most common side effect of chemotherapeutics, this has raised concerns regarding the increased risk of post-operative complications. The objective of present study is to examine the risk of post-operative wound complications in patients receiving neoadjuvant chemotherapy for breast cancer.

Methods: This study was conducted on 60 patients of breast carcinoma admitted for treatment to Nehru Hospital, BRDMC Gorakhpur for treatment during the period of July 2016-December 2017.

Results: Seroma formation was most common complication observed in 20% (12/60) patients followed by superficial surgical site infection in 6.67% (4/60) patients, Deep surgical site infection in 2 patients (3.33%). Wound dehiscence in 2 (3.33%) patients. These data suggested that no obvious increase in complications in patients gone for neoadjuvant chemotherapy.

Conclusions: Authors concluded that the rate of wound complications for breast cancer patients receiving Neoadjuvant chemotherapy is low. Seroma formation is the most frequent complication. Other complications can be avoided if proper preventive measures are taken. Smoking, hypertension, DM and obesity were associated with an increased risk of wound complications for patients undergoing BCS or MRM.


Deep surgical site infection, Flap necrosis, Neoadjuvant chemotherapy, Seroma, Superficial surgical site infection, Wound dehiscence

Full Text:



Kaufmann M, Von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007;18(12):1927-34.

Loibl S, von Minckwitz G, Raab G, Blohmer J-U, Dan Costa S, Gerber B, et al. Surgical procedures after neoadjuvant chemotherapy in operable breast cancer: results of the GEPARDUO trial. Ann Surg Oncol. 2006;13(11):1434-42.

Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26(5):778-85.

Waljee JF, Newman LA. Neoadjuvant systemic therapy and the surgical management of breast cancer. Surg Clin North Am. 2007;87(2):399-415.

Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JPA. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008; 100(24):1780-91.

El-Tamer MB, Ward BM, Schifftner T, Neumayer L, Khuri S, Henderson W. Morbidity and mortality following breast cancer surgery in women: national benchmarks for standards of care. Ann Surg. 2007;245(5):665-71.

Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21(22):4165-74.

Peled WA, Itakura K, Foster RD, Hamolsky D, Tanaka J, Ewing C, et al. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. Arch Surg. 2010;145(9):880-5.

Broadwater JR, Edwards MJ, Kuglen C, Hortobagyi GN, Ames FC, Balch CM. Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity. Ann Surg. 1991;213(2):126-9.

Hu Y-Y, Weeks CM, In H, Dodgion CM, Golshan M, Chun YS, et al. Impact of neoadjuvant chemotherapy on breast reconstruction. Cancer. 2011;117(13):2833-41.

Azzawi K, Ismail A, Earl H, Forouhi P, Malata CM. Influence of neoadjuvant chemotherapy on outcomes of immediate breast reconstruction. Plast Reconstr Surg. 2010;126(1):1-11.

Decker MR, Greenblatt DY, Havlena J, Wilke LG, Greenberg CC, Neuman HB. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surg. 2012;152(3):382-8.

Ranisavljević M, Selaković V, Lukić D, Radovanović Z, Vicko F. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Archive of Oncology. 2013 Jan;21(3-4):105-8.

Vilar-Compte D, Castillejos A, Hernandez-Mello N, Robles-Vidal C, Volkow P. Characteristics and treatment of surgical site complications in patients undergoing mastectomy at a cancer hospital in Mexico. Wounds. 2010;22(12):316-21.